OncoMatch/Clinical Trials/NCT06056362
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors
Is NCT06056362 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for neuroendocrine tumors.
This prospective, single-center, double-blinded study investigates the biodistribution, dosimetry, safety, and diagnostic ability of Al18F-NOTA-LM3 in patients with well-differentiated neuroendocrine tumors. And compares the diagnostic ability of Al18F-NOTA-LM3 with 68Ga-DOTATATE PET/CT and 68Ga-NODAGA-LM3 PET/CT. Clinical management will also be compared using different imaging modalities.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Prior therapy
Cannot have received: somatostatin analog
Exception: no long-acting somatostatin analog treatment within 4 weeks
No long-acting somatostatin analog treatment within 4 weeks
Cannot have received: peptide receptor radionuclide therapy
Exception: no PRRT treatment within 8 weeks
No PRRT treatment within 8 weeks
Lab requirements
Kidney function
gfr >= 30 ml/min
Liver function
alt/ast < 5 uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify